Cardiac biomarkers of atherothrombosis and their implication in estimating the risk of cardiovascular disease

Authors

Keywords:

cardiovascular risk factor, cardiovascular risk, biomarkers, prediction, homocysteine.

Abstract

Introduction: Innovative cardiovascular risk estimation strategies that use cardiac biomarkers of atherothrombosis have been shown to be superior in cardiovascular risk stratification that those predictions based exclusively on the evaluation of traditional risk factors in isolation. A bibliographic review, analysis and categorization of different articles was performed in the databases Cumed, Lilacs, Scielo, Medline, the key terms for the search were: "homocysteine", "lipoprotein (a)" and "cardiovascular risk", in Spanish, English and Portuguese languages. Original review articles were considered, including systematic reviews and published meta-analyzes after 2000.
Objective: To analyze some of the cardiac biomarkers of atherothrombosis that may be involved in the development of atherosclerotic cardiovascular disease and its thrombotic complications.
Development: Accumulated evidence supports that cardiac biomarkers such as: hyperhomocysteinemia, hyperlipoproteinemia (a), increased plasma fibrinogen levels, coagulant factor VII, Plasminogen Tissue Activator Inhibitor type 1 and C-reactive protein are tools of Very useful for stratifying cardiovascular risk in those individuals with intermediate risk, or with unusual or undefined risk, essentially in the field of primary and secondary prevention of cardiovascular disease.
Conclusions: The identification of additional predictive emergent atherothrombosis biomarkers is crucial for a more effective prevention and therapy of atherosclerotic cardiovascular disease.

Downloads

References

1. Toros Xavier H, Castellanos R, Fernández-Britto JE. Fibrinógeno y riesgo trombótico cardiovascular: algunas reflexiones. Rev Cubana Invest Biomed. 2005[acceso: 19/01/2020];24(3):[aprox. 15p.]. Disponible en: https://scielo.sld.cu/pdf/ibi/v24n3/ibi04305.pdf

2. Vega Abascal J, Guimará Mosqueda M, Vega Abascal L. Riesgo cardiovascular, una herramienta útil para la prevención de las enfermedades cardiovasculares. Rev Cubana Med Gen Integr. 2011 [acceso: 19/01/2020]; 27(1):91-97. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252011000100010

3. Tamayo Salazar E, Sánchez Soto JM, Estévez Ramos RA, Basset Machado I. Evaluación del riesgo cardiovascular mediante la aplicación de la tabla de Framingham. Rev Cubana Enfermer. 2017 [acceso: 16/01/2020]; 33(1):149-58. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03192017000100017&lng=es&nrm=iso&tlng=es

4. de Ruijter W, Westendorp R, Assendelft WJJ, den Elzen W PJ, de Craen AJM, le Cessie S, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009 [acceso: 11/01/2020]; 338:3083. Disponible en: https://www.bmj.com/content/338/bmj.a3083

5. Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019[acceso: 08/01/2020]; 17;140(25):2076-2088. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31707797

6. Leite LO, Faria Costa PR, Pereira da Conceiçao-Machado ME, Dias Pitangueira JC. Homocisteína y cisteína: marcadores de riesgo cardiovascular en adolescentes. Revista Adolescência e Saúde. 2018[acceso: 06/01/2020]; 15(4):104-113. Disponible en: https://www.adolescenciaesaude.com/detalhe_artigo.asp?id=751&id-ioma=Espanhol

7. Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P. Estándares SEA 2019 para el control global del riesgo cardiovascular. Clin Investig Arterioscler. 2019[acceso: 26/01/2020];31(S1):1-43. Disponible en: https://www.sciencedirect.com/journal/clinica-e-investigacion-en-arteriosclerosis/vol/31/suppl/S1

8. Achiong Alemañy M, Achiong Estupiñán F, Afonso de León JA, Álvarez Escobar MC, Suárez Merino M. Riesgo cardiovascular global y edad vascular: herramientas claves en la prevención de enfermedades cardiovasculares. Rev. Med. Electrón. 2016 [acceso: 12/02/2020]; 38(2):211-26. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242016000200010

9. Ruiz Mori E, Segura Vega L, Agusti Campos R. Uso del Score de Framingham como indicador de los factores de riesgo de las enfermedades cardiovasculares en la población peruana. Revista Peruana de Cardiología. 2012[acceso: 25/02/2020]; XXXVIII(3):1-19. Disponible en: https://www.revespcardiol.org/contenidos/static/premio_cardio/revista-peruana-cardiologia.pdf

10. Ruiz Mori E. Riesgo y Prevención Cardiovascular. Lima: Edición Lima; 2014.

11. Ruiz Mori E, Ruiz M H, Guevara Gonzales L, Ortecho Arias H, Salazar Rojas R, Torres Mallma C, et al. Factores de riesgo cardiovascular en mayores de 80 años. Horiz Med. 2015[acceso: 24/02/2020]; 15(3):26-33. Disponible en: https://www.redalyc.org/pdf/3716/371642259005.pdf

12. Escosa Royo L, Galache Osuna JG, Monzón Lomas F, Moreno Esteban E, Salazar González JJ, Sánchez-Rubio Lezcano J, et al. ¿es la homocisteína un factor de riesgo coronario?. Cardioaragon. 2003[acceso: 23/02/2020]; 7(1):[aprox. 15p.]. Disponible en: https://www.cardioaragon.com/revistas/volumen-7-numero-1/es-la-homocisteina-un-factor-de-riesgo-coronario/

13. Woo Kwon S, Kim JY, Ju Suh Y, Hyung Lee D, Won Yoo Y, Kwon Lee B. Prognostic Value of Elevated Homocysteine Levels in Korean Patients with Coronary Artery Disease: A Propensity Score Matched Analysis. Korean Circ J. 2016 [acceso: 23/02/2020];46(2):154-160. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805559/

14. Edin Zylberstein D, Bengtsson C, Björkelund C, Landaas S, Sundh V, Thelle D, Lissner L. Serum Homocysteine in Relation to Mortality and Morbidity From Coronary Heart Disease. A 24-Year Follow-Up of the Population Study of Women in Gothenburg. Circulation. 2004[acceso: 13/02/2020]; 109(5):601-6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14769681

15. Loukianos S R, Nikolaos K, Taxiarchoula R, Georgios P, Estela K, Maria Z. Homocysteine is an independent predictor of long-term cardiac mortality in patients with stable coronary artery disease in the era of statins. Coronary Artery Disease Journal. 2020[acceso: 05/01/2020];31(2):152-6. Disponible en: https://journals.lww.com/coronary-artery/Fulltext/2020/03000/Homocysteine_is_an_independent_predicto-r_of.8.aspx

16. Gupta S, Gudapati R, Gaurav K, Bhise M. Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocr Metab. 2013[acceso: 03/02/2020]; 17:806-14. Disponible en: https://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=5;spage=806;epage=814;aulast=Gupta

17. Tofler GH, Massaro J, O'Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA, et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thromb Res. 2016[acceso: 23/02/2020]; 140:30-35. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26896607

18. Santiso Ramos M, López Santiso P, Robert Companini L, Cabrera Espinosa O. Homocisteína, marcador de riesgo vascular. Revisión bibliográfica. MediCiego. 2016[acceso: 07/02/2020];22(4):[aprox. 10 p.]. Disponible en: https://www.revmediciego.sld.cu/index.php/mediciego/article/view/564/1065

19. Sontakke AN, Tilak MA, Dhat VV, More UM, Shinde SA, Phalak P, et al. Prevalence of Elevated Serum Homocysteine and Serum Lipoprotein "a" in Women. Journal of Clinical and Diagnostic Research : JCDR. 2014[acceso: 23/02/2020]; 8(10):13-5. Disponible en: https://doi.org/10.7860/JCDR/2014/9607.4995

20. Machado F, Reyes X. ¿Qué debe saber el cardiólogo clínico sobre la lipoproteína (a)? Rev. Urug. Cardiol. 2019[acceso: 23/02/2020]; 34 (3): 333-340. Disponible en: https://www.scielo.edu.uy/pdf/ruc/v34n3/1688-0420-ruc-34-03-260.pdf

21. Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016[acceso: 21/02/2020]; 2:7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471681/

22. Wang Z, Zhai X, Xue M, Cheng W, Hu H. Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis. Lipids Health Dis. 2019[acceso: 23/02/2020]; 18:150. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615167/

23. Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019[acceso:23/02/2020];13(3):374-392. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31147269

24. Canseco-Ávila LM, Jerjes-Sánchez C, Ortiz-López R, Rojas-Martínez A, Guzmán-Ramírez D. Fibrinógeno. ¿Factor o indicador de riesgo cardiovascular? Arch. Cardiol. Méx. 2006[acceso: 23/02/2020]; 76(supl.4):158-172. Disponible en: https://www.medigraphic.com/pdfs/archi/ac-2006/acs064o.pdf

25. Luc G, Bard J, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003[acceso: 22/02/2020]; 23(7):1255-61. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12775578

26. Ndrepepa G, Braun S, Tada T, King L, Cassese S, Fusaro M, et al. Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. Indian J Med Res. 2014[acceso: 13/02/2020]; 140(3): 392-400. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248386/

27. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115(16):2119-27. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17404162

28. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005[acceso: 23/02/2020];294(14):1799-1809. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16219884

29. Jiang P, Gao Z, Zhao W, Song Y, Tang XF, Xu JJ, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chin Med J (Engl). 2019[acceso: 23/02/2020];132(8):914-21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595753/

30. Comisión de Nuevos factores de riesgo. Revista Argentina de Cardiología. 2001 [acceso: 23/02/2020]; 69 (suplemento 1): 1-14. Disponible en: https://www.sac.org.ar/wp-content/uploads/2014/04/nuevosfactores.pdf

31. Jung RG, Motazedian P, Daniel Ramírez FD, Simard T, Di Santo P, Visintini S, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J. 2018[acceso: 19/02/2020]; 16:12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987541/

Downloads

Published

2021-04-01

How to Cite

1.
Rodríguez Perón JM. Cardiac biomarkers of atherothrombosis and their implication in estimating the risk of cardiovascular disease. Rev Cubana Med Milit [Internet]. 2021 Apr. 1 [cited 2025 Apr. 9];50(2):e0210766. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/766

Issue

Vol. 50 No. 2 (2021): April - June

Section

Review Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.